Blog

Photo from ESTRO/LinkedIn

Aug 26, 2024, 06:20

SBRT in Prostate Cancer at ESTRO24

European Society for Radiotherapy and Oncology (ESTRO) shared a post on LinkedIn:

“Five-year outcomes from the hypo-FLAME trial, acute toxicity results from the PACE-C trial, and key findings from the STORM trial were revealed at ESTRO24. Learn how SBRT is advancing treatment and improving outcomes in prostate cancer.”

Read further.
Source: ESTRO/LinkedIn

More posts featuring ESTRO24 on oncodaily.com

cancer David Pasquier ESTRO ESTRO24 European SocieTy for Radiotherapy and Oncology hypo-FLAME trial OncoDaily Oncology PACE-C trial prostate cancer radiation oncology SBRT SBRT in prostate cancer STORM trial

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage